Clinical trials
catalyst calendar across sponsors →Studies where ARTV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional
Held by 5 tracked-famous managers (VIKING GLOBAL INVESTORS LP, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP, Squarepoint Ops LLC) · FINRA short interest 5.1 days to cover (settled 2026-07-31) · insider 90d: 8 buys / 0 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114SafetyOpen-label · Treatment | Phase 2 | Recruiting | Drug: Allogeneic NK Cells | Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease | 90 | Jan 2028 | ≤ 529 d | 2026-07-31 |
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus ErythematosusNCT06265220Incidence of Treatment-Emergent Adverse Events and Serious Adverse EventsNon-randomized · Open-label · Treatment | Phase 1 | Active, not recruiting | Drug: AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab | Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLE | 51 | Aug 2027 | ≤ 376 d | 2025-12-10 |
| A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid TumorsNCT05678205Safety: incidence and severity of adverse events and serious adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Withdrawnsponsor's stated reason: Corporate business decision | Drug: AB-201, Cyclophosphamide, Fludarabine | Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 0 | Apr 2027 | ≤ 253 d | 2025-07-30 |
| AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin LymphomaNCT04673617Phase 1: Safety and tolerability of AB-101 as monotherapy, and in combination with rituximab (including the DLBCL specific cohort) and in combination with bendamustine and rituximab.Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: AB-101, Rituximab, Interleukin-2, Cyclophosphamide, Fludarabine, Bendamustine | Non Hodgkin Lymphoma | 45 | 2025-10-06actual | — | 2026-04-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19